Loading clinical trials...
Loading clinical trials...
Phase II Trial of VELCADE® (Bortezomib) for Steroid Refractory Acute GVHD
Conditions
Interventions
Bortezomib
Locations
1
United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Start Date
November 1, 2005
Primary Completion Date
September 1, 2008
Completion Date
September 1, 2009
Last Updated
May 4, 2025
NCT07070674
NCT00001529
NCT06910969
NCT06660355
NCT07166848
NCT06294691
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions